Skip to main content
Iterum Therapeutics plc logo

Iterum Therapeutics plc — Investor Relations & Filings

Ticker · ITRM ISIN · IE000TTOOBX0 US Manufacturing
Filings indexed 506 across all filing types
Latest filing 2026-03-31 Delisting Announcement
Country US United States of America
Listing US ITRM

About Iterum Therapeutics plc

https://www.iterumtx.com/

Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing differentiated anti-infectives to combat multi-drug resistant (MDR) pathogens. The company's lead product is sulopenem, a novel penem anti-infective compound developed in both oral and intravenous (IV) formulations. The oral formulation, ORLYNVAH™, has received U.S. FDA approval for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women caused by designated susceptible microorganisms. ORLYNVAH™ is the first oral penem antibiotic approved in the United States, addressing the need for new treatment options against the growing threat of antibiotic-resistant bacteria.

Recent filings

Filing Released Lang Actions
8-K - Iterum Therapeutics plc (0001659323) (Filer)
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the delisting of the company's shares from Nasdaq due to failure to maintain minimum bid price, the withdrawal of an appeal, and the winding up petition filed in Ireland. It also states that the company does not expect to file its Annual Report on Form 10-K or other future filings. The key event is the delisting notice and related procedural updates. This matches the definition of a Delisting Announcement (DLST). The document is not an Annual Report, Earnings Release, or other financial report but a regulatory current report announcing delisting and related events. The length and detail confirm it is the actual announcement, not a brief notice or report publication announcement.
2026-03-31 English
8-K - Iterum Therapeutics plc (0001659323) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes the filing of a winding up petition (bankruptcy/receivership), appointment of joint provisional liquidators, resignation of key executives, and a press release about the winding up petition. It also discusses the impact on financial obligations and trading suspension. This is not a full financial report, earnings release, or management discussion, but a regulatory announcement of significant corporate events. The document is about legal and financial distress events and changes in management authority, typical of a Regulatory Filing (RNS) rather than a full Audit Report or Annual Report. It is not a report publication announcement since it contains substantive event details, not just a notice of report availability. Therefore, the best classification is Regulatory Filings (RNS).
2026-03-27 English
8-K - ITERUM THERAPEUTICS PLC (0001659323) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, titled 'Current Report,' dated March 3, 2026. It discusses a delisting determination from Nasdaq due to failure to maintain minimum bid price and market value requirements, the company's request for a hearing to contest the delisting, and potential strategic alternatives including wind-down or bankruptcy. The content is focused on a significant corporate event related to stock exchange listing status and strategic options, not a financial report or earnings release. The document is not a full annual or quarterly report, audit report, or earnings release. It is a regulatory filing reporting a material event (delisting notice and related corporate developments). Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7903 characters) and detailed event description support this classification with high confidence.
2026-03-03 English
8-K - ITERUM THERAPEUTICS PLC (0001659323) (Filer)
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details a delisting determination from Nasdaq due to noncompliance with listing rules, including minimum bid price and market value requirements. It discusses the potential suspension of trading and the company's consideration of appealing the delisting. There is no financial data or comprehensive financial reporting, nor is it an earnings release or annual/interim report. The document is clearly an official notice of delisting and related events. Therefore, the appropriate classification is Delisting Announcement (DLST). The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2026-03-02 English
8-K - ITERUM THERAPEUTICS PLC (0001659323) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 18, 2026, reporting the results of shareholder votes at an Extraordinary General Meeting (EGM). It details voting outcomes on proposals related to share capital increase, directors' allotment authority, pre-emption rights opt-out, and reverse share split. The document explicitly states it is a "Current Report" pursuant to the Securities Exchange Act of 1934 and focuses on the submission of matters to a vote of security holders. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full financial report, earnings release, or proxy solicitation but a formal announcement of voting results. The length (7375 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive voting result report.
2026-02-18 English
DEF 14A
Proxy Solicitation & Information Statement
2026-01-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.